The success rate of CAR-T cell therapy varies for different types of cancer. According to the University of Chicago Medicine, the CAR T-cell therapy success rate is about 30% to 40% for lasting remission, with no additional treatment, as stated by Dr. Michael Bishop.
A study published in Nature Reviews Clinical Oncology demonstrated a complete remission (CR) rate of 55%, with 60% of these patients remaining in remission at 5 years. Additionally, Lancaster General Health mentions that the complete remission rates for chronic lymphocytic leukemia and non-Hodgkin lymphoma range from 35% to 70%, with about a third of these patients experiencing long-lasting remission.
It's important to note that CAR-T cell therapy has shown to be very effective against some types of hard-to-treat cancers, but it can also cause serious or life-threatening side effects and is typically used after other types of treatment have been tried.